Australia Red Biotechnology Market Size & Outlook, 2025-2030
The red biotechnology market in Australia is expected to reach a projected revenue of US$ 44,891.4 million by 2030. A compound annual growth rate of 15.4% is expected of Australia red biotechnology market from 2025 to 2030.
Revenue, 2024 (US$M)
$18,926.5
Forecast, 2030 (US$M)
$44,891.4
CAGR, 2025 - 2030
15.4%
Report Coverage
Australia
Global Market
Related Markets
Australia red biotechnology market highlights
- The Australia red biotechnology market generated a revenue of USD 18,926.5 million in 2024 and is expected to reach USD 44,891.4 million by 2030.
- The Australia market is expected to grow at a CAGR of 15.4% from 2025 to 2030.
- In terms of segment, monoclonal antibodies was the largest revenue generating product in 2024.
- Gene Therapy Products is the most lucrative product segment registering the fastest growth during the forecast period.
Red biotechnology market data book summary
| Market revenue in 2024 | USD 18,926.5 million |
| Market revenue in 2030 | USD 44,891.4 million |
| Growth rate | 15.4% (CAGR from 2025 to 2030) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Gene Therapy Products |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Monoclonal Antibodies, Polyclonal Antibodies, Recombinant Proteins, Vaccines, Cell-Based Immunotherapy Products, Gene Therapy Products, Cell Therapy Products, Tissue-Engineered Products, Stem Cells, Cell Culture, Viral Vector, Enzymes, Kits and Reagents, Animal Models, Molecular Diagnostics |
| Key market players worldwide | Merck KGaA, Roche Holding AG ADR, Pfizer Inc, Regeneron Pharmaceuticals Inc, AstraZeneca PLC, Gilead Sciences Inc, Biogen Inc, Amgen Inc, Bristol-Myers Squibb Co, Takeda Pharmaceutical Co Ltd |
Other key industry trends
- In terms of revenue, Australia accounted for 3.5% of the global red biotechnology market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan red biotechnology market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 54,951.1 million by 2030.
No credit card required*
Publish Date: Dec 03, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Red Biotechnology Market Scope
Red Biotechnology Market segmentation & scope
Others
Red Biotechnology Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Amgen Inc | View profile | 26,700 | One Amgen Center Drive, Thousand Oaks, CA, United States, 91320-1799 | www.amgen.com |
| Roche Holding AG ADR | View profile | 103,605 | Grenzacherstrasse 124, Basel, Switzerland, 4070 | www.roche.com |
| Merck KGaA | View profile | 62,345 | Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 | www.emdgroup.com |
| Pfizer Inc | View profile | 88,000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | www.pfizer.com |
| Bristol-Myers Squibb Co | View profile | 34,100 | Route 206 and Province Line Road, Princeton, New Jersey, NJ, United States, 08543 | www.bms.com |
| Regeneron Pharmaceuticals Inc | View profile | 13,450 | 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 | www.regeneron.com |
| AstraZeneca PLC | View profile | 89,900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | www.astrazeneca.com |
| Gilead Sciences Inc | View profile | 18,000 | 333 Lakeside Drive, Foster, CA, United States, 94404 | www.gilead.com |
| Biogen Inc | View profile | 7,570 | 225 Binney Street, Cambridge, MA, United States, 02142 | www.biogen.com |
| Takeda Pharmaceutical Co Ltd | View profile | 49,095 | 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, Japan, 103-8668 | www.takeda.com |
Australia Red Biotechnology Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Red Biotechnology Market Outlook will help companies and investors design strategic landscapes.
Monoclonal Antibodies was the largest segment with a revenue share of 57.41% in 2024.
Horizon Databook has segmented the Australia red biotechnology market based on monoclonal antibodies, polyclonal antibodies, recombinant proteins, vaccines, cell-based immunotherapy products, gene therapy products, cell therapy products, tissue-engineered products, stem cells, cell culture, viral vector, enzymes, kits and reagents, animal models, molecular diagnostics covering the revenue growth of each sub-segment from 2018 to 2030.
- Australia Red Biotechnology Market Product Outlook (Revenue, USD Million , 2018-2030)
- Monoclonal Antibodies
- Polyclonal Antibodies
- Recombinant Proteins
- Vaccines
- Cell-Based Immunotherapy Products
- Gene Therapy Products
- Cell Therapy Products
- Tissue-Engineered Products
- Stem Cells
- Cell Culture
- Viral Vector
- Enzymes
- Kits and Reagents
- Animal Models
- Molecular Diagnostics
- Others
- Australia Red Biotechnology Market End-user Outlook (Revenue, USD Million , 2018-2030)
- Academic Research Institutes
- CMOs & CROs
- Pharmaceutical & Biotechnology Companies
- Others
Reasons to subscribe to Red Biotechnology Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Red Biotechnology Market Outlook databook
- Our clientele includes a mix of Red Biotechnology Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia Red Biotechnology Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Australia Red Biotechnology Market Outlook from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Australia Red Biotechnology Market, 2018-2030 (US$M)
Australia red biotechnology market statistics, by product, 2018-2030 (US$M)
